At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B financing led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.
The mid-year conference’s goal was to bring together a promising group of 75 private and microcap companies in 25 different healthcare sectors with a prominent group of European and U.S. institutional investor groups.
Delcath’s Percutaneous Hepatic Perfusion (PHP) technology allows physicians to deliver significantly higher doses of existing chemotherapy drugs to the liver without exposing each patient’s entire body to the anti-cancer drugs.
Access Pharma (OTC: ACCP.OB) provided an update today on the status of its cobalamin-based oral drug delivery product development programs.
On 10/19/09, BioElectronics (OTC: BIEL.PK) announced the initial results from the pilot section of its ongoing acetaminophen comparison study.
OneMedPlace recently interviewed CEO Jeffrey Davis about the Dallas-based company’s pipeline.
OneMedPlace recently sat down with Jeffrey Davis, CEO of Access Pharmaceuticals, to discuss the clinical success of MuGard and the latest news surrounding the product’s launch.
Oral mucositis is a nearly inevitable complication for patients undergoing chemotherapy or radiation treatment for head or neck cancer.
Copyright © 2025 | WordPress Theme by MH Themes